Lepu Medical: Phase II clinical trial of the holding subsidiary MWN109 injection completed the first subject dosing.

Luopu Medical announced that its controlling subsidiary, MinWei Biotech, is conducting Phase II clinical trials for the innovative drug MWN109 injection for the treatment of obesity or overweight. The first subject has recently been successfully dosed. MWN109 injection is a GLP-1/GIP/GCG receptor triple agonist with global intellectual property rights. The drug stimulates pancreatic cells to secrete insulin to control blood sugar, increases satiety to reduce energy intake, promotes fat breakdown to increase energy expenditure and basal metabolism to reduce weight. Currently, the drug is in the early stages of research and development, with high uncertainty in subsequent clinical trials, high investment in research and development, long clinical trial periods, and risks of clinical trial failure.